This content was created by the National Sleep Foundation

Low nocturnal melatonin secretion levels are associated with an increased risk of developing type 2 diabetes

Now, new research from Brigham and Women’s Hospital (BWH) finds that the amount of melatonin a person secretes during sleep may predict their risk of developing type 2 diabetes. 

“This is the first time that an independent association has been established between nocturnal melatonin secretion and type 2 diabetes risk,” said Dr. Ciaran McMullan, a researcher in the Renal Division and Kidney Clinical Research Institute at BWH. “Hopefully this study will prompt future research to examine what influences a person’s melatonin secretion and what is melatonin’s role in altering a person’s glucose metabolism and risk of diabetes.” Melatonin is a hormone that is produced by the brain and secreted into a person’s bloodstream. As melatonin is mainly produced at night, melatonin’s blood levels peak during the nightime allowing regulation of circadian rhythm.

For this study, researchers identified 370 women who developed diabetes while taking part in the Nurses’ Health Study and 370 control subjects of the same age and race. When the two groups were compared, researchers found the study participants with low levels of nocturnal melatonin secretion had about twice the risk of developing type 2 diabetes than participants with high levels of nocturnal melatonin secretion. The study accounted for other well-established risk factors for diabetes, such as body mass index, family history of diabetes and lifestyle factors including diet, exercise, smoking and sleep duration and still found that melatonin secretion remained a significant risk factor.